Recent research has disclosed that acute myeloid leukemia (AML)-MSCs are able to block the production of leukemia-reactive CTLs via a novel COX2/PG/NR4A/WNT signaling pathway, resulting in attenuation of anti-tumor immunity [115]. Here, JUP is linked to acute myeloid leukemia.